Recently, we have reported that both OL and its new peracetylated derivative, peracetylated-OL (Per-OL), attenuated kidney injury in pristane-induced systemic lupus erythematosus (SLE) model inhibiting pro-inflammatory biomarkers overexpression via activation of heme-oxygenase (HO)-1/Nuclear factor E2-related factor 2 (Nrf-2) antioxidant pathway and suppression of the Janus kinase (JAK-STAT), nuclear transcription factor-kappa B (NF-κB) and mitogen-activated protein kinases (MAPK) activations [21]. Here, SOAT1 is linked to systemic lupus erythematosus.